JP2007509059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509059A5 JP2007509059A5 JP2006535368A JP2006535368A JP2007509059A5 JP 2007509059 A5 JP2007509059 A5 JP 2007509059A5 JP 2006535368 A JP2006535368 A JP 2006535368A JP 2006535368 A JP2006535368 A JP 2006535368A JP 2007509059 A5 JP2007509059 A5 JP 2007509059A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heteroaryl
- compound
- aminoalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 heterocycloaryl Chemical group 0.000 claims 179
- 150000001875 compounds Chemical class 0.000 claims 79
- 125000000217 alkyl group Chemical group 0.000 claims 61
- 125000001072 heteroaryl group Chemical group 0.000 claims 47
- 125000004103 aminoalkyl group Chemical group 0.000 claims 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000000068 chlorophenyl group Chemical group 0.000 claims 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 102000009929 raf Kinases Human genes 0.000 claims 5
- 108010077182 raf Kinases Proteins 0.000 claims 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 4
- 229960005310 aldesleukin Drugs 0.000 claims 4
- 108700025316 aldesleukin Proteins 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 claims 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims 4
- 125000001769 aryl amino group Chemical group 0.000 claims 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims 4
- 239000012965 benzophenone Substances 0.000 claims 4
- 150000005347 biaryls Chemical group 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 125000004799 bromophenyl group Chemical group 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 4
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229960003901 dacarbazine Drugs 0.000 claims 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 4
- 125000004986 diarylamino group Chemical group 0.000 claims 4
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 4
- 125000004212 difluorophenyl group Chemical group 0.000 claims 4
- 125000005240 diheteroarylamino group Chemical group 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 4
- 235000008191 folinic acid Nutrition 0.000 claims 4
- 239000011672 folinic acid Substances 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- 125000006485 halo alkoxy phenyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005059 halophenyl group Chemical group 0.000 claims 4
- 125000005241 heteroarylamino group Chemical group 0.000 claims 4
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 4
- 229960002411 imatinib Drugs 0.000 claims 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000006303 iodophenyl group Chemical group 0.000 claims 4
- 229940084651 iressa Drugs 0.000 claims 4
- 229960004768 irinotecan Drugs 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 229960001691 leucovorin Drugs 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000006501 nitrophenyl group Chemical group 0.000 claims 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 4
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 4
- 229960004641 rituximab Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 4
- 229950006410 tezacitabine Drugs 0.000 claims 4
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 4
- 229930192474 thiophene Natural products 0.000 claims 4
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 claims 4
- 229960000303 topotecan Drugs 0.000 claims 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 claims 3
- 125000004360 trifluorophenyl group Chemical group 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51185103P | 2003-10-16 | 2003-10-16 | |
| PCT/US2004/034185 WO2005037285A1 (en) | 2003-10-16 | 2004-10-15 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509059A JP2007509059A (ja) | 2007-04-12 |
| JP2007509059A5 true JP2007509059A5 (https=) | 2007-09-06 |
Family
ID=34465285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535368A Pending JP2007509059A (ja) | 2003-10-16 | 2004-10-15 | 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20050084835A1 (https=) |
| EP (1) | EP1680122A1 (https=) |
| JP (1) | JP2007509059A (https=) |
| KR (1) | KR20070029110A (https=) |
| CN (1) | CN1882345A (https=) |
| AU (1) | AU2004281154A1 (https=) |
| CA (1) | CA2542329A1 (https=) |
| IL (1) | IL174470A0 (https=) |
| MX (1) | MXPA06003607A (https=) |
| WO (1) | WO2005037285A1 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20060292537A1 (en) * | 2005-06-27 | 2006-12-28 | Arcturus Media, Inc. | System and method for conducting multimedia karaoke sessions |
| CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| ES2344760T3 (es) | 2006-07-20 | 2010-09-06 | Amgen Inc. | Compuestos de piridona sustituidos y metodo de uso. |
| US20100216791A1 (en) * | 2006-08-17 | 2010-08-26 | Astrazeneca | Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors |
| TW200829566A (en) * | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| WO2008102353A2 (en) * | 2007-02-20 | 2008-08-28 | Mobile Star Corp. | Self operated computerized karaoke recording booth |
| AU2008303602A1 (en) * | 2007-09-27 | 2009-04-02 | F. Hoffmann-La Roche Ag | Quinoline derivatives as 5HT5A receptor antagonists |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX2010004246A (es) * | 2007-10-18 | 2010-04-30 | Novartis Ag | Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas. |
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PE20091561A1 (es) * | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
| JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 |
| ES2392482T3 (es) * | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| SI2947072T1 (sl) | 2008-03-17 | 2017-03-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni |
| AU2009334869A1 (en) | 2008-12-29 | 2011-07-14 | Fovea Pharmaceuticals | Substituted quinazoline compounds |
| SG173610A1 (en) | 2009-02-13 | 2011-09-29 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| BRPI1011247A2 (pt) | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| SI2440547T1 (sl) * | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| KR101630283B1 (ko) * | 2009-06-25 | 2016-06-14 | 한화테크윈 주식회사 | 영상 보안 시스템에서 부호화 장치 |
| PH12012500382A1 (en) | 2009-09-03 | 2012-10-22 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US8553906B2 (en) * | 2010-02-02 | 2013-10-08 | Creative Technology Ltd | Apparatus for enabling karaoke |
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| KR20180099933A (ko) | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | 복소환 아민 및 이의 용도 |
| CA2823753C (en) * | 2011-01-05 | 2019-03-12 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| CA2846574C (en) * | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors |
| CN108794411B (zh) * | 2011-09-14 | 2022-06-07 | 润新生物公司 | 某些化学实体、组合物及方法 |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| RU2659786C2 (ru) | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
| EP2897618B1 (en) * | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| CN103896922B (zh) * | 2012-12-25 | 2017-05-03 | 上海科胜药物研发有限公司 | 新的舒尼替尼盐及其制备方法 |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| EP3548007A4 (en) | 2016-12-01 | 2020-08-12 | Ignyta, Inc. | METHOD OF TREATMENT OF CANCER |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2020061470A1 (en) * | 2018-09-21 | 2020-03-26 | Spectrum Pharmaceuticals, Inc. | Novel quinazoline egfr inhibitors |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| US12528796B2 (en) * | 2019-04-15 | 2026-01-20 | Tosk, Inc. | Modulators of RAS GTPase |
| CN111072500B (zh) * | 2019-11-15 | 2022-12-06 | 山东罗欣药业集团恒欣药业有限公司 | 一种盐酸氨溴索的制备方法 |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| US12180220B2 (en) * | 2020-10-14 | 2024-12-31 | Tosk, Inc. | Heteroaryl modulators of RAS GTPase |
| US20220112178A1 (en) * | 2020-10-14 | 2022-04-14 | Tosk, Inc. | Small Molecule Modulators of RAS GTPase |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2739505A (en) * | 1952-02-04 | 1956-03-27 | Gillette Edwin | Method and means for producing composite talking pictures |
| GB900779A (en) * | 1959-04-22 | 1962-07-11 | Monsanto Chemicals | Quinazolines |
| US3177218A (en) | 1962-01-17 | 1965-04-06 | Monsanto Chemicals | Methylene-bis(2-guanidino-4-methylquinazoline) |
| US4149190A (en) * | 1977-10-17 | 1979-04-10 | Xerox Corporation | Automatic gain control for video amplifier |
| US4408221A (en) * | 1981-09-22 | 1983-10-04 | Mccoy Reginald F H | Television chroma-key systems |
| DK190983A (da) | 1982-05-01 | 1983-11-02 | Wellcome Found | 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor |
| US5051817A (en) * | 1988-11-18 | 1991-09-24 | Rohm Co., Ltd. | Superimposing system |
| JP3206619B2 (ja) * | 1993-04-23 | 2001-09-10 | ヤマハ株式会社 | カラオケ装置 |
| JP3542821B2 (ja) * | 1994-03-31 | 2004-07-14 | ヤマハ株式会社 | 映像合成システムに特徴を有するカラオケ装置 |
| US5541666A (en) * | 1994-07-06 | 1996-07-30 | General Instrument | Method and apparatus for overlaying digitally generated graphics over an analog video signal |
| JP3662969B2 (ja) * | 1995-03-06 | 2005-06-22 | 富士通株式会社 | カラオケシステム |
| CN1110969C (zh) * | 1995-04-21 | 2003-06-04 | 索尼公司 | 图像信号的相位同步方法、电路及合成装置 |
| US6400374B2 (en) * | 1996-09-18 | 2002-06-04 | Eyematic Interfaces, Inc. | Video superposition system and method |
| JP2957977B2 (ja) * | 1997-10-30 | 1999-10-06 | 三洋電機株式会社 | ビデオカメラ |
| US6514083B1 (en) * | 1998-01-07 | 2003-02-04 | Electric Planet, Inc. | Method and apparatus for providing interactive karaoke entertainment |
| EP1072263A4 (en) * | 1998-03-26 | 2004-03-31 | Japan Tobacco Inc | AMID DERIVATIVES AND NOCICEPTINANT AGONISTS |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20020072047A1 (en) * | 1999-12-13 | 2002-06-13 | Michelson Daniel R. | System and method for generating composite video images for karaoke applications |
| CN100335479C (zh) * | 1999-12-17 | 2007-09-05 | 希龙公司 | 糖元合成酶激酶3的双环抑制剂 |
| US6978051B2 (en) * | 2000-03-06 | 2005-12-20 | Sony Corporation | System and method for capturing adjacent images by utilizing a panorama mode |
| KR20020026374A (ko) * | 2000-06-20 | 2002-04-09 | 요트.게.아. 롤페즈 | 가라오케 시스템 |
| EP1337513A1 (en) * | 2000-11-02 | 2003-08-27 | AstraZeneca AB | 4-substituted quinolines as antitumor agents |
| CA2443950C (en) | 2001-04-20 | 2011-10-18 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7035915B1 (en) * | 2001-09-05 | 2006-04-25 | Cisco Technology, Inc. | Method and apparatus for IP address assignment |
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2004092144A2 (en) * | 2003-04-16 | 2004-10-28 | F. Hoffmann-La Roche Ag | Quinazoline compounds useful as p38 kinase inhibitors |
| US20070047834A1 (en) * | 2005-08-31 | 2007-03-01 | International Business Machines Corporation | Method and apparatus for visual background subtraction with one or more preprocessing modules |
| US7570881B2 (en) * | 2006-02-21 | 2009-08-04 | Nokia Corporation | Color balanced camera with a flash light unit |
-
2004
- 2004-10-15 CN CNA200480030549XA patent/CN1882345A/zh active Pending
- 2004-10-15 CA CA002542329A patent/CA2542329A1/en not_active Abandoned
- 2004-10-15 AU AU2004281154A patent/AU2004281154A1/en not_active Abandoned
- 2004-10-15 US US10/966,073 patent/US20050084835A1/en not_active Abandoned
- 2004-10-15 US US10/966,358 patent/US7691866B2/en not_active Expired - Fee Related
- 2004-10-15 JP JP2006535368A patent/JP2007509059A/ja active Pending
- 2004-10-15 MX MXPA06003607A patent/MXPA06003607A/es unknown
- 2004-10-15 EP EP04795363A patent/EP1680122A1/en not_active Withdrawn
- 2004-10-15 KR KR1020067007130A patent/KR20070029110A/ko not_active Ceased
- 2004-10-15 WO PCT/US2004/034185 patent/WO2005037285A1/en not_active Ceased
-
2006
- 2006-03-21 IL IL174470A patent/IL174470A0/en unknown
-
2009
- 2009-09-04 US US12/554,748 patent/US20090317359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509059A5 (https=) | ||
| JP2007507428A5 (https=) | ||
| JP2005529089A5 (https=) | ||
| JP2007509058A5 (https=) | ||
| TW591022B (en) | Tetrahydropyridino or piperidino heterocyclic derivatives | |
| AU2009231885B2 (en) | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | |
| US7317031B2 (en) | Substituted triazole diamine derivatives as kinase inhibitors | |
| EP1682126B1 (en) | Substituted benzazoles and use thereof as inhibitors of raf kinase | |
| JP5261370B2 (ja) | キナーゼ阻害剤としてのピリジル及びピリミジニル置換されたピロール、チオフェン及びフラン誘導体 | |
| US7067537B2 (en) | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | |
| RU2515972C2 (ru) | Диазакарбазолы и способы применения | |
| MXPA05007990A (es) | Compuestos de tienopirimidina y uso de los mismos. | |
| JP2011513279A (ja) | Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| JP2007517843A (ja) | Ｃｈｋ１阻害剤であるチオフェン誘導体 | |
| US20100292210A1 (en) | Novel Compounds for A-Beta-Related Pathologies | |
| JP2010502717A (ja) | インターロイキン１受容体関連キナーゼの調節物質 | |
| CN103874494A (zh) | 使用pi3k/mtor的吡啶并嘧啶酮抑制剂与苯达莫司汀和/或利妥昔单抗治疗恶性血液病的组合疗法 | |
| KR20010086471A (ko) | 도파민-ｄ3-수용체 친화성을 갖는 트리아졸 화합물 | |
| JP2012530763A (ja) | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 | |
| KR20150138858A (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| CZ20021220A3 (cs) | Aminotriazolopyridinové deriváty | |
| RU2350609C2 (ru) | Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний | |
| WO2005058858A1 (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder | |
| EP2621916A1 (en) | Benzazole derivatives as histamine h4 receptor ligands | |
| RU2008151722A (ru) | 1, 3-дизамещенные 4-метил-1н-пиррол-2-карбоксамиды и их применение для изготовления лекарственных средств |